Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lymphoma, Large B-Cell, Diffuse 2Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Ascites 1Advanced Solid Tumours 1Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck 1Advanced Solid Malignancies 1

Interventions

Quality of Life 2Nutritional Status 2Interviews as Topic 2sintilimab 1danvatirsen 1contrast agent BR1 1catumaxomab 1aflibercept 1Zoledronic Acid 1Vascular Access Devices 1Portasystemic Shunt, Transjugular Intrahepatic 1Octreotide 1Hyperthermic Intraperitoneal Chemotherapy 1Catheters, Indwelling 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ascites × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡